Actively Recruiting
A Study of SPY002-091 in Healthy Volunteers
Led by Spyre Therapeutics, Inc. · Updated on 2025-08-17
56
Participants Needed
1
Research Sites
81 weeks
Total Duration
On this page
Sponsors
S
Spyre Therapeutics, Inc.
Lead Sponsor
A
Altasciences Company Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a Phase 1, randomized, double-blind, placebo-controlled, single- dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-091 in healthy participants.
CONDITIONS
Official Title
A Study of SPY002-091 in Healthy Volunteers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy men and women
- Willing and able to attend the necessary visits to the CRU
- Able to comply with all testing requirements
- Able to remain at the study site unit for the duration of the confinement period
- Able to return for the outpatient visits
You will not qualify if you...
- Participation in more than one cohort
- Evidence of clinically significant abnormality or disease
- Known history of illicit drug use or drug abuse, harmful alcohol use or alcoholism, and/or smoking or nicotine-containing product use within 3 months prior to the first dose of study drug
- History of severe allergic reactions or hypersensitivity
- Donation or loss of more than 1 unit of whole blood within 1 month prior to dosing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Spyre Site 1
Cypress, California, United States, 90630
Actively Recruiting
Research Team
M
Medical Director, Clinical Development
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here